

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

BAUSCH HEALTH IRELAND LIMITED
Patent Owner.

Case IPR2022-01105
Patent 9,925,231

**MYLAN PHARMACEUTICALS INC.'S
UPDATED NOTICE UNDER
37 C.F.R. § 42.8(a)(3)**

Petitioner Mylan Pharmaceuticals Inc. (Mylan) submits the following mandatory change-of-information notices for IPR2022-01105.

A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Unchanged

Petitioner Mylan Pharmaceuticals Inc. (“Mylan”) is a co-defendant with Mylan Laboratories Ltd., Mylan Inc., and Viatris Inc. in parallel litigation.

Although Agila Specialties Inc. and Mylan API US LLC were also named as defendants in the administratively-closed Western District of Pennsylvania litigation (see below), they are not real parties-in-interest. They were dismissed from the case now in the Northern District of West Virginia and were the subject of a motion to dismiss when the Pennsylvania case was administratively closed.

B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Updated

Mylan Pharmaceuticals Inc. v. Bausch Health Ireland Ltd., IPR2022-00722 (PTAB) (IPR2023-00016 joined); and *Bausch Health Ireland Ltd. v. Mylan Laboratories Ltd.*, 1-22-cv00020 (NDWV); 2-21-cv-00573 (WDPA) (administratively closed); and *Bausch Health Ireland Ltd. v. MSN Laboratories Pvt. Ltd.*, 2-21-cv-10057 (DNJ). IPR2022-01102, IPR2022-01103, and IPR2022-01104 involve patents closely related to the challenged patent.

Patent owner Bausch has identified pending application 17/207,222 (under final rejection) as related.

C. Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Updated

Lead: Jad Mills, Reg. No. 63,344.

First Backup: Richard Torczon, Reg. No. 34,448.

Backup: ~~Nicole Stafford, Reg. No. 43,929, and~~¹

Dennis Gregory, Reg. No. 52,967.

Postal Address: 701 Fifth Avenue, Suite 5100, Seattle, WA 98104-7036.

Telephone: 206-883-2554.

Facsimile: 206-883-2699.

D. Electronic Service - Updated

Mylan consents to electronic-mail service at: jmills@wsgr.com,
rtorczon@wsgr.com, dgregory@wsgr.com, and [4881-7825-
5901@mail.vault.netdocuments.com](mailto:4881-7825-5901@mail.vault.netdocuments.com).

Respectfully submitted,

Date: 20 March 2023

/Richard Torczon/
Richard Torczon, Reg. No. 34,448
Counsel for Mylan Pharmaceuticals, Inc.

¹ No longer at Wilson Sonsini.

CERTIFICATE OF SERVICE

I certify that today this paper was served on the Patent Owner at the Patent Owner's email correspondence addresses as follows:

Justin J. Hasford	justin.hasford@finnegan.com
Bryan C. Diner	bryan.diner@finnegan.com
Joshua L. Goldberg	joshua.goldberg@finnegan.com
Kassandra M. Officer	kassandra.officer@finnegan.com
Lauren J. Robinson	lauren.robinson@finnegan.com
Caitlin E. O'Connell	caitlin.o'connell@finnegan.com
Kyu Yun Kim	kyuyun.kim@finnegan.com

Respectfully submitted,

Date: March 20, 2023

/Robyn Moriarty
Robyn Moriarty